Sickle Cell Disease in New York: An Overview
About 100,000 Americans are affected by sickle cell disease (SCD), the most prevalent genetic blood disorder in the U.S.
Roughly 10% of those patients are located in New York State, with a significant concentration in New York City. Researchers at New York University School of Global Public Health analyzed data from 42,200 hospitalized SCD patients in the state between 2009 and 2022 to examine aspects like hospital stays, costs, disease severity, and mortality risk.
Interestingly, while New York City had the most SCD hospitalizations overall, Long Island had the highest percentage (10%) of hospitalizations where there was a notable risk of mortality.
“This indicates a significant burden of sickle cell disease on Long Island,” noted study author Emeka Iloegbu. “The costs were also elevated in both Long Island and New York City, possibly reflecting more complex cases or differences in the way specialty care is provided.”
SCD stems from mutations in genes responsible for hemoglobin production, affecting mostly individuals of African descent. This genetic mutation leads to the formation of crescent-shaped blood cells that struggle to transport oxygen, thereby increasing the risk of organ damage, anemia, strokes, infections, and severe pain for patients.
Patients often need hospitalization for various treatments, and Iloegbu mentions that several factors, such as the presence of specialized sickle cell teams and emergency procedures for crises, can impact their treatment experience.
The study highlighted that central New York patients had the longest average stays (6.3 days) in hospitals, closely followed by the Hudson Valley (6.2 days). In contrast, patients in New York City had shorter stays (5.5 days) and faced lower risks of mortality.
The total hospital costs were highest on Long Island, which reflects the significant financial burden of living with SCD. Some estimates suggest that individuals with private insurance could incur lifetime medical costs of about $1.7 million, along with out-of-pocket expenses nearing $44,000.
A substantial majority (83%) of hospitalized individuals in New York were Black, with the most hospitalizations occurring among adults aged 18 to 29 years (40%), followed by those aged 30 to 49 years (32%). Researchers believe the data indicates shortcomings in transitioning SCD patients from pediatric to adult care.
Alarmingly, the rate of “severe” hospitalizations for SCD has surged from 13% in 2009 to 27% in 2022, with those categorized under “severe mortality risk” rising from 3% to 13%. The researchers link this increase to complications arising from COVID-19 and the disruptions to care during the pandemic.
The findings were shared in a recent publication by JAMA Network Open.
Those behind the research hope their insights can lead to enhanced care for SCD patients. “Recognizing regional differences in sickle cell disease can help detect and address care disparities,” remarked study author Emmanuel Peprah.
Addressing these disparities involves improving access to specialists and educating healthcare providers on treatment protocols. The team also advocates for increased funding for SCD, updates to public health policy, and enhanced availability of effective treatments to alleviate the pressure on emergency departments.
Since 1975, New York State has had the nation’s first SCD newborn screening program, which aids in early diagnosis and intervention—key factors in improving health outcomes. However, shifting migration patterns mean many patients seeking SCD treatment in New York weren’t screened as infants.
“These individuals often can only engage with the healthcare system through emergency departments rather than through earlier testing,” Iloegbu explained. “The fact that some regions in New York are experiencing higher severity and longer hospital stays demonstrates an urgent need for better surveillance, particularly at a patient level.”
While Long Island faces a considerable burden from SCD, it is also at the forefront of treatment innovations. Last year, a local hospital successfully used gene therapy to eliminate SCD in a patient.
